Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC.
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2015
At a glance
- Drugs Cisplatin; Docetaxel; Etoposide; Filgrastim; Pegfilgrastim
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 19 Apr 2012 Actual patient number is 26 according to ClinicalTrials.gov.
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.